Business Description
10x Genomics Inc
NAICS : 621999
SIC : 8099
ISIN : US88025U1097
Share Class Description:
MEX:TXG: Ordinary Shares - Class ADescription
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 5.33 | |||||
| Equity-to-Asset | 0.78 | |||||
| Debt-to-Equity | 0.11 | |||||
| Debt-to-EBITDA | -0.72 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 2.84 | |||||
| Beneish M-Score | -4.07 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 4.5 | |||||
| 3-Year EBITDA Growth Rate | -70.8 | |||||
| 3-Year EPS without NRI Growth Rate | -41.7 | |||||
| 3-Year FCF Growth Rate | 63.1 | |||||
| 3-Year Book Growth Rate | -7.2 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 23.16 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 3.93 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-1 Month Momentum % | -65.91 | |||||
| 6-1 Month Momentum % | -65.91 | |||||
| 12-1 Month Momentum % | -59.16 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.37 | |||||
| Quick Ratio | 4.68 | |||||
| Cash Ratio | 3.96 | |||||
| Days Inventory | 156.35 | |||||
| Days Sales Outstanding | 47.5 | |||||
| Days Payable | 33.48 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.8 | |||||
| Shareholder Yield % | 0.82 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 68.36 | |||||
| Operating Margin % | -29.07 | |||||
| Net Margin % | -25.14 | |||||
| EBITDA Margin % | -17.83 | |||||
| FCF Margin % | 7.18 | |||||
| ROE % | -21.92 | |||||
| ROA % | -17.02 | |||||
| ROIC % | -39.1 | |||||
| 3-Year ROIIC % | -133.29 | |||||
| ROC (Joel Greenblatt) % | -38.28 | |||||
| ROCE % | -18.96 | |||||
| Moat score | 5 | |||||
| Tariff score | 7 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 2.28 | |||||
| PB Ratio | 2.04 | |||||
| Price-to-Tangible-Book | 2.1 | |||||
| Price-to-Free-Cash-Flow | 32.23 | |||||
| Price-to-Operating-Cash-Flow | 25.17 | |||||
| EV-to-EBIT | -7 | |||||
| EV-to-Forward-EBIT | -6.68 | |||||
| EV-to-EBITDA | -9.64 | |||||
| EV-to-Forward-EBITDA | -8.32 | |||||
| EV-to-Revenue | 1.72 | |||||
| EV-to-Forward-Revenue | 1.85 | |||||
| EV-to-FCF | 24.74 | |||||
| Price-to-GF-Value | 0.3 | |||||
| Price-to-Net-Current-Asset-Value | 3.77 | |||||
| Price-to-Net-Cash | 6.27 | |||||
| Earnings Yield (Greenblatt) % | -14.29 | |||||
| FCF Yield % | 3.12 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
10x Genomics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil MXN) | 12,233.388 | ||
| EPS (TTM) (MXN) | -25.469 | ||
| Beta | -0.43 | ||
| 3-Year Sharpe Ratio | -0.81 | ||
| 3-Year Sortino Ratio | -0.87 | ||
| Volatility % | 85.92 | ||
| 14-Day RSI | - | ||
| 14-Day ATR (MXN) | 0.242768 | ||
| 20-Day SMA (MXN) | 150 | ||
| 12-1 Month Momentum % | -59.16 | ||
| 52-Week Range (MXN) | 150 - 440 | ||
| Shares Outstanding (Mil) | 123.13 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
10x Genomics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
10x Genomics Inc Stock Events
| Event | Date | Price (MXN) | ||
|---|---|---|---|---|
| No Event Data | ||||
10x Genomics Inc Frequently Asked Questions
What is 10x Genomics Inc(MEX:TXG)'s stock price today?
The current price of MEX:TXG is MXN150.00. The 52 week high of MEX:TXG is MXN440.00 and 52 week low is MXN150.00.
When is next earnings date of 10x Genomics Inc(MEX:TXG)?
The next earnings date of 10x Genomics Inc(MEX:TXG) is 2025-08-08 Est..
Does 10x Genomics Inc(MEX:TXG) pay dividends? If so, how much?
10x Genomics Inc(MEX:TXG) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers